Mutagenic and clastogenic activity of gastric juice in human gastric diseases.

[1]  M. Blaser,et al.  Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. , 2000, Journal of the National Cancer Institute.

[2]  A. Axon,et al.  In vivo DNA damage in gastric epithelial cells. , 2000, Mutation research.

[3]  Walsh,et al.  Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[4]  I. Emerit,et al.  Clastogenic factors: biomarkers of oxidative stress of potential utility in the clinical chemistry laboratory. , 1999, Annals of clinical and laboratory science.

[5]  M. Rugge,et al.  Oxidative DNA damage accumulation in gastric carcinogenesis , 1998, Gut.

[6]  P. Hrelia,et al.  Cytogenetic effects of Metalaxyl on human and animal chromosomes. , 1996, Mutation research.

[7]  M. Chung,et al.  Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. , 1996, Cancer research.

[8]  F. Cuccurullo,et al.  Antioxidant properties of omeprazole , 1996, FEBS letters.

[9]  I. Modlin,et al.  Genotoxicity, carcinogenicity and acid-suppressing medications. , 1995, Pharmacology & therapeutics.

[10]  I. Emerit.  Reactive oxygen species, chromosome mutation, and cancer: possible role of clastogenic factors in carcinogenesis. , 1994, Free radical biology & medicine.

[11]  W. W. Nichols,et al.  Comments on the report of 'association' of omeprazole with DNA by Phillips et al. , 1992, Mutagenesis.

[12]  S. Selway,et al.  Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomach. , 1991, Mutation research.

[13]  H. Helander,et al.  Structure and function of rat parietal cells during treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine. , 1990, Scandinavian journal of gastroenterology.

[14]  H. Evans.  Tests for genotoxicity: principles and findings in relation to omeprazole. , 1990, Digestion.

[15]  R. Goodlad,et al.  Omeprazole and genotoxicity , 1990, The Lancet.

[16]  B. Burlinson,et al.  Genotoxicity studies of gastric acid inhibiting drugs , 1990, The Lancet.

[17]  I. Emerit.  [58] Clastogenic factors: Detection and assay , 1990 .

[18]  A. Axon,et al.  The mutagenic activity of gastric juice. , 1988, Mutation research.

[19]  P. Correa,et al.  A human model of gastric carcinogenesis. , 1988, Cancer research.

[20]  S. De Flora,et al.  Circadian monitoring of gastric juice mutagenicity. , 1987, Mutagenesis.

[21]  R. Stockbruegger.  Bacterial overgrowth as a consequence of reduced gastric acidity. , 1985, Scandinavian journal of gastroenterology. Supplement.

[22]  P. Hrelia,et al.  NADPH-generating system: influence on microsomal mono-oxygenase stability during incubation for the liver-microsomal assay with rat and mouse S9 fractions. , 1984, Mutation research.

[23]  D. Morris,et al.  Mutagenicity in gastric juice. , 1984, Gut.

[24]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[25]  S. Flora.  CIMETIDINE, RANITIDINE, AND THEIR MUTAGENIC NITROSO DERIVATIVES , 1981, The Lancet.

[26]  S. Tannenbaum,et al.  The gastric microenvironment in populations at high risk to stomach cancer. , 1979, National Cancer Institute monograph.

[27]  Pilkington Tl.  NEW ACCIDENT DEPARTMENT. , 1963 .